Systemic GHK-Cu does different things from locally applied GHK-Cu, and the dose-response curves are different
The compounds work when handled correctlythe variable is technique, not individual response
FDA banned it in late 2023 "Category 2: Substance with Safety Concerns" Why the FDA banned it: Potential immune reactions (immunogenicity) Manufacturing impurities in compounded versions Complete lack of human safety data Risk of contamination Legal status: NOT FDA-approved Illegal to compound in pharmacies Banned by WADA for athletes Possession not illegal (it's not a DEA scheduled substance) Sold online as "research chemical" 2
In research and emerging clinical use, 5-Amino-1MQ has been associated with: Keep expectations grounded: these are research-supported possibilities, not guarantees, and individual results vary
Compound Comparison Feature Class BPC-157 15-amino-acid synthetic pentadecapeptide TB-500 Synthetic 17-amino-acid Thymosin Beta-4 fragment Feature Common research focus BPC-157 Tendon, gut, vessel models
Published material on the related Pliva development codes PL-10, PLD-116, and PL-14736 has concentrated on preclinical wound, tissue-protection, and gastrointestinal-injury models rather than randomized human efficacy data, and the peer-reviewed record does not contain a confirmatory efficacy readout for the indications most commonly associated with BPC-157 in informal discussion